^
    Back
    Association details:
    Biomarker:HER-2 positive
    Cancer:Colon Cancer
    Drug:Kadcyla (ado-trastuzumab emtansine) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for HER2 Positive Breast Cancer)
    New
    Title:

    Trastuzumab emtansine (Kadcyla®) is accepted for use within NHSScotland.

    Excerpt:
    Trastuzumab emtansine...as a single agent, is indicated for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Eur J Clin Invest
    Title:

    Application of trastuzumab emtansine in HER-2-positive and KRAS/BRAF-mutated colon cancer cells

    Published date:
    05/01/2020
    Excerpt:
    The results showed that T-DM1 had better inhibitory effect than cetuximab and trastuzumab on LS174T and HT-29 cells….The results of this study suggested that T-DM1 has potential in the treatment of HER-2-positive colon cancer cells…
    DOI:
    10.1111/eci.13255